Drug treatment for obesity in the post-sibutramine era
Language: 
English
Abstract: 

Obesity is a major health problem worldwide. It is associated with cardiovascular diseases, diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are essential; pharmacological therapy may be added for obese patients or overweight patients with cardiovascular risk factors. Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis. It reduces bodyweight by about 4.2?kg after 12 months, and improves blood glucose and lipids; however, it can increase heart rate and blood pressure. In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients. There is now a clear need to find anti-obesity drugs that are effective and safe in the long term.

Author(s): 
Cheung, Bernard M. Y.
Item Type: 
Journal Article
Publication Title: 
Drug Safety: An International Journal of Medical Toxicology and Drug Experience
Journal Abbreviation: 
Drug Saf
Publication Date: 
8/1/2011
Publication Year: 
2011
Pages: 
641-650
Volume: 
34
Issue: 
8
ISSN: 
0114-5916
DOI: 
10.2165/11592040-000000000-00000
Library Catalog: 
NCBI Published Medical (?)
Extra: 
PMID: 21751825

Turabian/Chicago Citation

Bernard M. Y. Cheung. 8/1/2011. "Drug treatment for obesity in the post-sibutramine era." Drug Safety: An International Journal of Medical Toxicology and Drug Experience 34: 8: 641-650. 10.2165/11592040-000000000-00000.

Wikipedia Citation

<ref> {{Cite journal | doi = 10.2165/11592040-000000000-00000 | issn = 0114-5916 | volume = 34 | pages = 641-650 | last = Cheung | first = Bernard M. Y. | coauthors = | title = Drug treatment for obesity in the post-sibutramine era | journal = Drug Safety: An International Journal of Medical Toxicology and Drug Experience | date = 8/1/2011 | pmid = | pmc = }} </ref>